Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient | Zendy

Aart Jan van der Lely | Zendy; Alex F. Muller | Zendy; J. A. M. J. L. Janssen | Zendy; Robert J. Davis | Zendy; Kenneth Zib | Zendy; John A. Scarlett | Zendy; Steven W. J. Lamberts | Zendy

Open Access

Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient

Author(s) -

Aart Jan van der Lely,

Alex F. Muller,

J. A. M. J. L. Janssen,

Robert J. Davis,

Kenneth Zib,

John A. Scarlett,

Steven W. J. Lamberts

Publication year - 2001

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jcem.86.2.7206

Subject(s) - pegvisomant , acromegaly , antagonist , endocrinology , medicine , octreotide , receptor , hormone , pharmacology , growth hormone , somatostatin

We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research